How to appeal a UnitedHealthcare immune globulin (ivig/scig) for pidd denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for immune globulin (ivig/scig) for pidd

Cited policy: UHC/OptumRx Immune Globulin (IVIG/SCIG) for Primary Immunodeficiency — Medical Benefit Drug Policy

Diagnosis of PIDD per AAAAI/ACAAI Practice Parameter (Bonilla 2015) — quantitative immunoglobulin abnormality (IgG <2 SD below age mean OR IgG subclass deficiency OR specific antibody deficiency with impaired vaccine response) AND clinical history of recurrent/severe infections AND exclusion of secondary causes. Dosing 300-800 mg/kg IV q3-4 wk targeting trough >=500 mg/dL (UHC) — or per immunologist target. Reauth at 6-12 mo with trough + clinical response.

How UnitedHealthcare denies immune globulin (ivig/scig) for pidd — and how to counter it

Where UnitedHealthcare pushes back: 1) IgG only mildly low — does not meet 2 SD threshold; 2) Vaccine response not documented; 3) Brand-specific formulary swap (Privigen → Gammagard); 4) Trough target too high.

Counter-arguments that hold up: Cite Bonilla 2015 SS — diagnosis based on IgG + functional impairment + clinical infection burden together, not single threshold. ESID 2019 criteria require vaccine-response failure for CVID. Document post-Pneumovax / Hib / tetanus titer failure. Excipient + reaction documentation supports brand specificity (proline vs glycine vs sorbitol vs maltose). Orange Clin Immunol 2010 — trough >=700-1000 mg/dL reduces pneumonia 27% per 100 mg/dL; >=500 is suboptimal floor in patients with breakthroughs or bronchiectasis.

What UnitedHealthcare typically denies for immune globulin (ivig/scig) for pidd

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For immune globulin (ivig/scig) for pidd, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the immune globulin (ivig/scig) for pidd treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Privigen (IVIG)
• Gamunex-C (IVIG)
• Octagam (IVIG)
• Gammagard Liquid (IVIG)
• Flebogamma DIF (IVIG)
• Bivigam (IVIG)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.